Taysha Gene Therapies, Inc. – NASDAQ:TSHA
Founder-led company
Taysha Gene Therapies stock price today
$2.81
+1.06
+60.57%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Taysha Gene Therapies stock price monthly change
-26.16%
month
Taysha Gene Therapies stock price quarterly change
-26.16%
quarter
Taysha Gene Therapies stock price yearly change
+0.86%
year
Taysha Gene Therapies key metrics
Market Cap | 374.02M |
Enterprise value | N/A |
P/E | -0.21 |
EV/Sales | -14.98 |
EV/EBITDA | 0.15 |
Price/Sales | 11.96 |
Price/Book | 31.54 |
PEG ratio | -0.01 |
EPS | -1.15 |
Revenue | 14.15M |
EBITDA | -78.50M |
Income | -118.00M |
Revenue Q/Q | -27.51% |
Revenue Y/Y | 96.39% |
Profit margin | -9991.93% |
Oper. margin | -9780.18% |
Gross margin | 0% |
EBIT margin | -9780.18% |
EBITDA margin | -554.54% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTaysha Gene Therapies stock price history
Taysha Gene Therapies stock forecast
Taysha Gene Therapies financial statements
| Jun 2023 | 2.39M | -24.59M | -1027.06% |
|---|---|---|---|
| Sep 2023 | 4.74M | -117.08M | -2467.07% |
| Dec 2023 | 3.60M | 47.74M | 1324.67% |
| Mar 2024 | 3.41M | -24.06M | -705.39% |
| Sep 2025 | 3.10M | -21.50M | -693.34% |
|---|---|---|---|
| Oct 2025 | 2.44M | -26.75M | -1095.65% |
| Dec 2025 | 3.8M | -15.08M | -396.95% |
| Dec 2025 | 2.2M | -27.41M | -1246.33% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 81543000 | 118.65M | 145.51% |
|---|---|---|---|
| Sep 2023 | 195769000 | 244.88M | 125.09% |
| Dec 2023 | 266994000 | 192.05M | 71.93% |
| Mar 2024 | 152999000 | 99.15M | 64.8% |
| Jun 2023 | -18.76M | 48K | 377K |
|---|---|---|---|
| Sep 2023 | -17.94M | -3.49M | 140.63M |
| Dec 2023 | -16.11M | -10K | -4.24M |
| Mar 2024 | -19.81M | -140K | -4K |
Taysha Gene Therapies alternative data
| Aug 2023 | 65 |
|---|---|
| Sep 2023 | 65 |
| Oct 2023 | 65 |
| Nov 2023 | 65 |
| Dec 2023 | 65 |
| Jan 2024 | 65 |
| Feb 2024 | 65 |
| Mar 2024 | 52 |
| Apr 2024 | 52 |
| May 2024 | 52 |
| Jun 2024 | 52 |
| Jul 2024 | 52 |
Taysha Gene Therapies other data
20.75%
-26.58%
of TSHA is owned by hedge funds
28
-23
9.12M
-10.25M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2023 | 5000 | 0 |
| Jun 2023 | 0 | 463223 |
| Jul 2023 | 0 | 85872 |
| Aug 2023 | 17800000 | 33000 |
| Nov 2023 | 100000 | 0 |
| Quarter | Transcript |
|---|---|
| Q1 2024 15 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 19 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q1 2023 11 May 2023 | Q1 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Kamran Alam CPA, M.B.A. (1978) Chief Financial Officer | $756,380 |
Mr. R. A. Session II (1979) Founder, Pres, Chief Executive Officer & Director | $634,630 |
Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M (1970) Chief Medical Officer and Head of R&D | $501,780 |
Abeona Therapeutics: pz-cel Has Massive Potential For RDEB Patients
Taysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited Opportunity
Taysha Gene Therapies Is Showing Promise For Rett Syndrome
Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued
Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones
Acadia Pharmaceuticals: Back In The Buy Zone
Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'
Taysha Gene Therapies: Rett Syndrome Data Makes This A Must Watch
Taysha: The FDA Just Stuck A Major Blow To Their Plans
-
What's the price of Taysha Gene Therapies stock today?
One share of Taysha Gene Therapies stock can currently be purchased for approximately $2.81.
-
When is Taysha Gene Therapies's next earnings date?
Unfortunately, Taysha Gene Therapies's (TSHA) next earnings date is currently unknown.
-
Does Taysha Gene Therapies pay dividends?
No, Taysha Gene Therapies does not pay dividends.
-
How much money does Taysha Gene Therapies make?
Taysha Gene Therapies has a market capitalization of 374.02M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 517.55% to 15.45M US dollars.
-
What is Taysha Gene Therapies's stock symbol?
Taysha Gene Therapies, Inc. is traded on the NASDAQ under the ticker symbol "TSHA".
-
What is Taysha Gene Therapies's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Taysha Gene Therapies?
Shares of Taysha Gene Therapies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Taysha Gene Therapies's key executives?
Taysha Gene Therapies's management team includes the following people:
- Mr. Kamran Alam CPA, M.B.A. Chief Financial Officer(age: 47, pay: $756,380)
- Mr. R. A. Session II Founder, Pres, Chief Executive Officer & Director(age: 46, pay: $634,630)
- Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M Chief Medical Officer and Head of R&D(age: 55, pay: $501,780)
-
Is Taysha Gene Therapies founder-led company?
Yes, Taysha Gene Therapies is a company led by its founder Mr. R. A. Session II.
-
How many employees does Taysha Gene Therapies have?
As Jul 2024, Taysha Gene Therapies employs 52 workers.
-
When Taysha Gene Therapies went public?
Taysha Gene Therapies, Inc. is publicly traded company for more then 4 years since IPO on 24 Sep 2020.
-
What is Taysha Gene Therapies's official website?
The official website for Taysha Gene Therapies is tayshagtx.com.
-
Where are Taysha Gene Therapies's headquarters?
Taysha Gene Therapies is headquartered at 3000 Pegasus Park Drive, Dallas, TX.
-
How can i contact Taysha Gene Therapies?
Taysha Gene Therapies's mailing address is 3000 Pegasus Park Drive, Dallas, TX and company can be reached via phone at 214 612 0000.
Taysha Gene Therapies company profile:
Taysha Gene Therapies, Inc.
tayshagtx.comExchange:
NASDAQ
Full time employees:
52
Industry:
Biotechnology
Sector:
Healthcare
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
3000 Pegasus Park Drive
Dallas, TX 75247
Dallas, TX 75247
CIK: 0001806310
ISIN: US8776191061
CUSIP: 877619106
